Evidence map›Paper›PMID 41104244›Full record

ArticleIranian journal of pharmaceutical research : IJPR

Integrating Network Pharmacology and Experimental Validation to Identifying Key Herbal Components and Targets for Liver Cancer.

Fang Wang, Shenghao Li, Xiling Liu, Yi Xu, Huimin Yan

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fang WangHebei Medical University, Shijiazhuang, China.
Shenghao LiThe Fifth Hospital of Shijiazhuang, Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, Shijiazhuang, China.
Xiling LiuHebei Medical University, Shijiazhuang, China.
Yi XuThe Fifth Hospital of Shijiazhuang, Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, Shijiazhuang, China.
Huimin YanHebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Traditional Chinese medicines (TCMs) offer a comprehensive approach to managing malignant tumors. Objectives: The present study aims to predict the high-frequency herbs, core components, and core targets for liver cancer treatment through data mining and network pharmacology. Methods: The "traditional Chinese Medicine - active components - target - disease" network was established using Cytoscape to identify core components. A protein-protein interaction (PPI) network was constructed using the STRING database, and Cytoscape was used for network topological analysis to identify the core targets. Subsequently, molecular docking was performed using AutoDock Vina and PyMOL to calculate binding energies of core components with core targets. Furthermore, in vitro experiments explored quercetin's impact on liver cancer cell migration, apoptosis, and protein expression. Results: A total of 50 high-frequency drugs were selected. Among these, Conclusions: This study provides a foundational basis for future clinical application of TCMs in liver cancer treatment.

Indexed as

AP-1Heat-ClearingInvigorating qiLiver CancerTraditional Chinese Medicine

Identifiers

PMID41104244
PMCPMC12524083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.